Current Diabetes Reports

, Volume 9, Issue 3, pp 185–187 | Cite as

ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks

  • HoWon Lee
  • Amgad N. Makaryus
  • Samy I. McFarlane
Clinical Trials Report

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Flather MD, Yusuf S, Kober L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575–1581.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677.PubMedGoogle Scholar
  3. 3.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259.Google Scholar
  4. 4.
    McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H–37H.PubMedCrossRefGoogle Scholar
  5. 5.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.Google Scholar
  6. 6.
    McFarlane SI, Borer JS: Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials. Curr Diab Rep 2009, 9:1–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  9. 9.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.PubMedCrossRefGoogle Scholar
  10. 10.
    van de Wal RM, Plokker HW, Lok DJ, et al.: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006, 106:367–372.PubMedCrossRefGoogle Scholar
  11. 11.
    Carey RM: Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005, 14:67–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.PubMedGoogle Scholar
  13. 13.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  14. 14.
    Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181–188.PubMedCrossRefGoogle Scholar
  15. 15.
    McDowell SE, Coleman JJ, Ferner RE: Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006, 332:1177–1181.PubMedCrossRefGoogle Scholar
  16. 16.
    Yusuf S, Teo K, Anderson C, et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174–1183.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • HoWon Lee
  • Amgad N. Makaryus
  • Samy I. McFarlane

There are no affiliations available

Personalised recommendations